The research results of the research team were reported by more than dozens of media and video websites, including Singularity, Zhihu, Toutiao, Anhui News Network, etc
Zhang Jun, Director of the Oncology Department at Ruijin Hospital, in collaboration with our research group, designed and initiated a “basket” clinical trial using arsenic trioxide to treat p53 mutant cancer patients
The European Anti Cancer Foundation TP53 Trust and the International Clinical Research Organization REDO have invited Researcher Lu Min to explore the feasibility, risk benefit ratio, and open discussion of intermittent low-dose arsenic dosing for the prevention and treatment of p53 congenital mutation related cancers in the patient population
The research achievements of the research team, together with the other nine events, such as the overseas approval of the domestic COVID-19 vaccine and the promulgation of the Chinese Pharmacopoeia, were rated as the top ten pharmaceutical events in China in 2020 by the Journal of Pharmacy
